Table 1. Main characteristics and results of the eligible studies.
| First author-year | Patients source | Histology | Stage | N pts | Method | Positive (%) | HR estimation | Survival results |
|---|---|---|---|---|---|---|---|---|
| Zhang 2014 | China | AC | I-III | 143 | IHC | NA | HR and 95% CI 1.98 (1.01-3.89) | Poor |
| Velcheti 2013 Yale cohort | USA | NSCLC | I-IV | 155 | IHC | 36.1 | Survival curves 1.43 (1.12-2.14) | Poor |
| Velcheti 2013 Greek cohort | Greece | NSCLC | I-IV | 303 | IHC | 24.8 | Survival curves 1.32 (1.09-1.75) | Poor |
| Chen YB 2012 | China | NSCLC | I-III | 120 | IHC | 57.5 | HR and 95% CI 2.95 (1.63-4.38) | Poor |
| Ma W 2011 | China | NSCLC | I-IV | 47 | IHC | 48.9 | Survival curves 1.48 (1.15-1.97) | Poor |
| Wu 2011 | China | NSCLC | I-III | 109 | IHC | 53.2 | Survival curves 1.39 (1.08-1.87) | Poor |
N pts, number of patients; HR, hazard ratio; AC, adenocarcinoma; IHC, immunohistochemistry; NA, not applicable; CI, confidence interval; NSCLC, non-small cell lung cancer.